2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

BACKGROUND: Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell lymphoma and acute B lymphocytic leukemia treatment. However, treatment of T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yingxi, Liu, Qian, Zhong, Mengjun, Wang, Zhenzhen, Chen, Zhaoqi, Zhang, Yu, Xing, Haiyan, Tian, Zheng, Tang, Kejing, Liao, Xiaolong, Rao, Qing, Wang, Min, Wang, Jianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524286/
https://www.ncbi.nlm.nih.gov/pubmed/31097020
http://dx.doi.org/10.1186/s13045-019-0732-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524286/
https://www.ncbi.nlm.nih.gov/pubmed/31097020
http://dx.doi.org/10.1186/s13045-019-0732-7

Ejemplares similares